IL-17A Inhibitor (Secukinumab) on Cardiovascular and Renal Endpoints in Cardiorenal Metabolic Syndrome With ASCVD
Cardiorenal Metabolic Syndrome · Atherosclerotic Cardiovascular Disease
Enrolment: 100 · Results not recorded
Loading the evidence…
Biologic
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Cardiorenal Metabolic Syndrome · Atherosclerotic Cardiovascular Disease
Enrolment: 100 · Results not recorded
Psoriatic Arthritis
Enrolment: 166 · Results not recorded
Psoriasis
Enrolment: 327 · Results not recorded
Psoriatic Arthritis
Enrolment: 394 · Results not recorded
Bullous Pemphigoid
Enrolment: 4 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Bilateral full mid-substance transection of the medial collateral ligament in the transverse plane, under isoflurane anaesthesia
IL-17 neutralisation significantly decreased M2 macrophages in the healing region (p = 0.001), increased T cells across the ligament (p = 0.05) and increased IL-2, IL-6 and IL-12 (p = 0.004, 0.014 and 0.03) at 7 days, while IL-10 and IL-1 beta were unchanged. Wound area, wound length, type I procol…
Extraction: extract · Supplied extraction confidence: 0.93. Machine-extracted fields require source verification.